Federated Hermes, Inc. Gamida Cell Ltd. Transaction History

Federated Hermes, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$1.15 - $2.1 $10,639 - $19,429	9,252 Added 0.6%	1,547,600 $2 Million
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.39 $505,738 - $1.12 Million	-330,548 Reduced 17.69%	1,538,348 $2.45 Million
Q2 2022 Aug 15, 2022	SELL	$1.73 - $4.29 $5.64 Million - $14 Million	-3,259,404 Reduced 63.56%	1,868,896 $3.31 Million
Q1 2022 May 13, 2022	BUY	$2.22 - $4.47 $1.7 Million - $3.42 Million	764,985 Added 17.53%	5,128,300 $21.3 Million
Q4 2021 Feb 14, 2022	SELL	$2.2 - $4.46 $711,150 - $1.44 Million	-323,250 Reduced 6.9%	4,363,315 $11.1 Million
Q1 2021 May 13, 2021	SELL	$7.8 - $12.43 $2.85 Million - $4.55 Million	-365,958 Reduced 7.24%	4,686,565 $37.9 Million
Q4 2020 Feb 12, 2021	BUY	$4.07 - $11.0 $13.3 Million - $36 Million	3,274,746 Added 184.2%	5,052,523 $42.4 Million
Q2 2020 Aug 13, 2020	BUY	$2.79 - $6.5 $4.96 Million - $11.6 Million	1,777,777 New	1,777,777 $8.12 Million

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.